Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — Q2 2021 Earnings Presentation
17 slides from Laboratorio Reig Jofre's earnings presentation, 2021
Slide 1: Results Second Quarter of 2021
RESULTS Second Quarter of 2021 1
Slide 2: Disclaimer
DISCLAIMER This presentation may contain forward-looking statements including statements about Reig Jofre's intent, beliefs and expectations with respect to business and operations, market conditions, operating income and financial conditions, capital adequacy, specific provisions and risk managemen
Slide 3: Table of Contents
TABLE OF CONTENTS 01. 2021 RESULTS 02. PERFORMANCE OF THE BUSINESS UNITS 03. INCOME STATEMENT AND BALANCE SHEET 04. OUTLOOK FOR 2021 05. RJF SHARE PERFORMANCE PAGE 3
Slide 4: Q2 2021 Results: Business Units
Q2 2021 RESULTS BUSINESS UNITS PAGE 4
Slide 5: Sales and EBITDA consolidated
REIG JOFRE's sales figure held steady in the first half of 2021 achieving 3% growth in its EBITDA SALES The first half closed with sales of €116 million, at a level similar to the first half of 2020. Recovery €116.1 million from the sale of prescription medical products from the Speciality Pharmac
Slide 6: Revenues by Business Unit
Revenues by Business Unit PHARMACEUTICAL The Pharmaceutical Technologies division declined 6% in the first quarter of 2021, due to the lower TECHNOLOGIES demand for essential medicines. Antibiotics The consumption of antibiotic products is notably reduced by the COVID prevention measures, a tren
Slide 7: Sales by Geographical Region
Rest of Rest of SPAIN EUROPE WORLD Sales by Geographical Region. 47% 40% 13% €54.2 million €46.8 €15.1 million % International Sales* España Unión 47% Europea The Spanish market remained at the PHARMACEUTICAL 34% previous year's level, with a slight reduction of 1%, due to lower TECHNOLOGIES 51% c
Slide 8: Income Statement and Balance Sheet
Q2 2021 INCOME STATEMENT BALANCE SHEET PAGE 8
Slide 9: Income Statement
Income Statement Q2 2021 Performance A slight increase in the sales figure in this first half, which nevertheless allows for a better gross margin, standing at 62.3% of sales, from 60.3% with which the same period of the previous year closed, due to the lower margin associated with essential medic
Slide 10: Balance sheet: CAPEX 2021
Balance sheet Q2 2021 CAPEX 2021 R&D 11.1 € million CAPITALISATION CAPEX INDUSTRIAL 2.3 million 8.8 million Capital expenditure on industrial capacity and technology totalling €8.8 million. The two main projects are: on the one hand the renovation of facilities and infrastructures at the Antibioti
Slide 11: Balance sheet: net financial debt
Balance sheet Q2 2021 NET FINANCIAL DEBT Debt|EBITDA 53.2 Q2, 2021 Q2, 2021 year- € million year- 2.0 end end 2020 year- 55.1 € million 2020 year- 2.1 end end FINANCIAL LEASE DEBT DEBT UNDER IFRS 16 10.8million 69.4million CORPORATE DEBT CREDIT AND OTHER 58.6million 11 Non-current liabilities are
Slide 12: Outlook for 2021
Q2 2021 OUTLOOK FOR 2021 PAGE 12
Slide 13: Outlook for 2021
Outlook for 2021 After closing 2020 with sales of €230 million, with a 15% growth driven by the sale of essential medicines and the impact of the incorporation of the new osteoarticular product business, 2021 closed this first half at the same level of sales as the same period of the previous year,
Slide 14: RJF Share Performance
Q2 2021 RJF SHARE PERFORMANCE PAGE 14
Slide 15: RJF Share Performance Jul '20 – Jun '21
RJF Share Performance Jul ’20 – Jun ’21 Market capitalisation of €382 million Data as at 30 June 2021 Close REIG JOFRE 2021 30/06/21 6,50 Close 6,25 31/12/20 €4.97 Following completion of the Scrip Dividend 6,00 €4.39 distribution in July 2021, Reig Jofre’s capital is 5,75 divided into 77,802,279 sh
Slide 16: Links and Further Information
LINKS AND FURTHER INFORMATION LATEST NEWS www.reigjofre.com/en/news SUBSCRIPTION CENTRE http://www.reigjofre.com/en/news/subscription-center PAGE 16
Slide 17: Thank you
Table of Thank you Av. de les Flors 08970 Sant Joan Despi, Barcelona, Spain Tel. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com